The role of CD40L in resistance to enteric infection
- Institution
- University of Pennsylvania, PA
- Principal investigator
- Christopher A Hunter
- Funding
- $441K
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
Project Summary The ability of recently activated T cells to express the cell surface molecule CD40L allows them to communicate with other immune and non-immune populations. This molecule is of particular importance in the gut to help control the parasitic infection caused by Cryptosporidium. Here we leverage a novel, natural mouse model of Cryptosporidium to dissect the impact of the CD40-CD40L interaction in T cell-mediated resistance to infection in the gut. In this model, WT mice (like humans) develop sterile immunity mediated by T cell production of IFN-γ, but mice that lack CD40L mice (like humans) do not resolve infection. In addition, treatment of chronically infected CD40L-deficient mice with soluble (s)CD40L results in rapid parasite clearance. We will test if protective effect of CD40L may be explained by either I. its ability to promote T cell responses essential for resistance and/or II. because CD40L directly activates EC to limit parasite growth. We are uniquely equipped to utilize parasite transgenesis, combined with sophisticated genetic approaches to define the key cellular interactions that allows CD40L to determine the outcome of an enteric infection.
Research team
- Christopher A HunterPI
- Boris StriepenPI
LOADING MOONBASE SCORE
Questions for University of Pennsylvania
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of PennsylvaniaNot yet scored
The role of CD40L in resistance to enteric infection
Christopher A Hunter · $524K · 2021–2026
- NIH · University of PennsylvaniaNot yet scored
Immunity to Cryptosporidium
Christopher A Hunter · $777K · 2020–2029
- NIH · University of Pennsylvania70
Epitranscriptomic regulation in the mammalian nervous system
Guo-Li Ming · $985K · 2024–2032